ArticleCanadian journal of gastroenterology & hepatology2026
Prognostic Value and Related Molecular Mechanisms of miR-5003-3p in Hepatocellular Carcinoma.
Article in Canadian journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value and Related Molecular Mechanisms of miR-5003-3p in Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a malignant tumor worldwide with a high mortality rate and recurrence rate. Numerous miRNAs are being applied to the healing and prognosis of HCC. A prior investigation predicted that miR-5003-3p was linked to HCC, but the relevant molecular mechanisms were not clear.
aimTo discover the prognostic value and molecular mechanisms concerned of miR-5003-3p in HCC.
methodsA total of 125 tumor specimens from HCC patients were obtained in this study, along with corresponding adjacent noncancerous tissue samples collected as a control. The levels of miR-500-3p and MAL2 in tumor tissues and cells were detected by RT-qPCR. The prognostic value of miR-500-3p was evaluated using Kaplan-Meier curve and COX regression model. The effects of miR-500-3p on cellular malignant phenotypes were assessed via CCK-8 and Transwell assays. The target sites of miR-500-3p were identified using bioinformatics analysis. The dual-luciferase reporter assay validated the target relationship between them.
resultsmiR-5003-3p levels were remarkably elevated in HCC tissues, and late TNM stage (I + II) was dramatically higher versus early TNM stage (III + IV). Lymph node metastasis, TNM stage, and differentiated degree were linked notably to miR-5003-3p expression. Upregulated miR-5003-3p was an independent risk factor for HCC. In vitro, downregulated miR-5003-3p could induce apoptosis and restrain proliferation, migration, and invasion, which could be rescued by depressed MAL2.
conclusionmiR-5003-3p may be an independent prognostic factor for HCC. Mechanistically, miR-5003-3p negatively regulates MAL2 to promote cellular processes. These findings highlight the potential of miR-5003-3p as a novel prognostic biomarker and a promising therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.